Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:16:20.641Z.
Calculation as of: 2026-10-06T14:16:20.641Z.
Quote observation: 2026-10-06T14:12:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.80M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.10M
EV/Sales Ratio
60.87x
TTM Avg
59.29x
3Y Avg
19360.66x
5Y Avg
791152.03x
Market Cap
$5.21M
EV/Sales Ratio
0.72x
TTM Avg
1.63x
3Y Avg
1.96x
5Y Avg
36.60x
Market Cap
$5.29M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.80M | N/A | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.92M | 1.03x | 0.52x | 1.80x | 5.65x |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | 60.87x | 59.29x | 19360.66x | 791152.03x |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | 0.72x | 1.63x | 1.96x | 36.60x |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.22M | 1.53x | 1.15x | 9.43x | 16.78x |
| Femasys Inc. (FEMY)vs › | $6.13M | 4.12x | 8.87x | 13.46x | 13.63x |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.10M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
